Amikacin exposure and susceptibility of macrolide-resistant Mycobacterium abscessus Source: ERJ Open Res, 5 (2) 00154-2018; 10.1183/23120541.00154-2018 Year: 2019
Bedaquiline as a potential agent in the treatment of Mycobacterium abscessus infections Source: Eur Respir J, 49 (5) 1700083; 10.1183/13993003.00083-2017 Year: 2017
Mycobacterium tuberculosis resistance Source: Eur Respir J 2002; 20: Suppl. 38, 360s Year: 2002
Bedaquiline as a potential agent in the treatment of M. intracellulare and M. avium infections Source: Eur Respir J , 49 (3) 1601969; DOI: 10.1183/13993003.01969-2016 Year: 2017
The spectrum of drug susceptibility of slow-growing nontuberculous mycobacteria (MAC, M. kansasii, M. xenopi) Source: International Congress 2017 – Clinical challenges in chronic lung diseases Year: 2017
In vitro susceptibility of M. avium against protionamide Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Fluoroquinolone resistance in multidrug-resistant Mycobacterium tuberculosis independent of fluoroquinolone use Source: Eur Respir J, 50 (6) 1701633; 10.1183/13993003.01633-2017 Year: 2017
In vitro susceptibility testing of bedaquiline against mycobacteria avium-intracellulare complex Source: Virtual Congress 2020 – Aspergillosis and chronic lung infections Year: 2020
The effects of drug resistance phenotype on proliferation of Mycobacterium tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 723s Year: 2004
Biological properties of Mycobacterium tuberculosis (Mtb) resistant to biocides Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis Year: 2021
Inhaled therapies, azithromycin and Mycobacterium abscessus in cystic fibrosis patients Source: Eur Respir J 2013; 41: 1101-1106 Year: 2013
The Glutoxim influence on minimum inhibitory concentration of isoniazid-resistant strains of Mycobacterium tuberculosis Source: International Congress 2019 – Tuberculosis: from basic science to patient care Year: 2019
Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis Source: Eur Respir J 2015; 46: 444-455 Year: 2015
Susceptibility of Mycobacterium tuberculosis strains to fluoquinolones, obtained from chronic patients with multidrug resistant pulmonary tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 315s Year: 2001
Paradoxical response during antibiotic treatment in patients with Mycobacterium avium complex lung disease Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis Year: 2020
Defining optimal fluoroquinolone exposure against Mycobacterium tuberculosis : contribution of murine studies Source: Eur Respir J, 57 (4) 2004315; 10.1183/13993003.04315-2020 Year: 2021
Pulmonary diseases caused by non-tuberculous mycobacteria Source: Eur Respir Mon 2012; 58: 25-37 Year: 2012
Characteristics of drug susceptibility of M. abscessus subsp. abscessus and M.chelonae Source: International Congress 2019 – Clinical investigations of non-TB mycobacterial infection Year: 2019
In vitro susceptibility of mycobacterium bovis against moxifloxacin Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Characterization of drug susceptibility of nontuberculous mycobacteria of M.chelonae and M.fortuitum complexes. Source: International Congress 2018 – Challenges in treating tuberculosis and nontuberculous mycobacteria Year: 2018